<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39423458</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2213-2317</ISSN><JournalIssue CitedMedium="Internet"><Volume>77</Volume><PubDate><Year>2024</Year><Month>Oct</Month><Day>05</Day></PubDate></JournalIssue><Title>Redox biology</Title><ISOAbbreviation>Redox Biol</ISOAbbreviation></Journal><ArticleTitle>Enhancing Gpx1 palmitoylation to inhibit angiogenesis by targeting PPT1.</ArticleTitle><Pagination><StartPage>103376</StartPage><MedlinePgn>103376</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.redox.2024.103376</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2213-2317(24)00354-9</ELocationID><Abstract><AbstractText>The significance of protein S-palmitoylation in angiogenesis has been largely overlooked, leaving various aspects unexplored. Recent identification of Gpx1 as a palmitoylated protein has generated interest in exploring its potential involvement in novel pathological mechanisms related to angiogenesis. In this study, we demonstrate that Gpx1 undergoes palmitoylation at cysteine-76 and -113, with PPT1 playing a crucial role in modulating the depalmitoylation of Gpx1. Furthermore, we find that PPT1-regulated depalmitoylation negatively impacts Gpx1 protein stability. Interestingly, inhibiting Gpx1 palmitoylation, either through expression of a non-palmitoylated Gpx1 mutant or by expressing PPT1, significantly enhances neovascular angiogenesis. Conversely, in PPT1-deficient mice, angiogenesis is notably attenuated compared to wild-type mice in an Oxygen-Induced Retinopathy (OIR) model, which mimics pathological angiogenesis. Physiologically, under hypoxic conditions, Gpx1 palmitoylation levels are drastically reduced, suggesting that increasing Gpx1 palmitoylation may have beneficial effects. Indeed, enhancing Gpx1 palmitoylation by inhibiting PPT1 with DC661 effectively suppresses retinal angiogenesis in the OIR disease model. Overall, our findings highlight the pivotal role of protein palmitoylation in angiogenesis and propose a novel mechanism whereby the PPT1-Gpx1 axis modulates angiogenesis, thereby providing a potential therapeutic strategy for targeting PPT1 to combat angiogenesis.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 The Authors. Published by Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Yidan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>The Third Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, 453000, China; Department of Neurosciences, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian, Kelantan, 16150, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yuan</LastName><ForeName>Xinxin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Sanquan College of Xinxiang Medical University, XinXiang 453003, Henan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wei</LastName><ForeName>Aodong</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>The Third Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, 453000, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xiaopeng</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>The Third Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, 453000, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patar</LastName><ForeName>Azim</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian, Kelantan, 16150, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Su</LastName><ForeName>Shaobo</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>The Third Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, 453000, China; State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, 510060, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Songtao</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Human Anatomy &amp; Histoembryology, School of Basic Medical Sciences, Xinxiang Medical University, Xinxiang, Henan, 453000, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Gaoen</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>The Third Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, 453000, China; The First Affiliated Hospital of Hainan Medical University, Haikou, 571199, China. Electronic address: 15757826611@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Jiangli</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>The Third Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, 453000, China; State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and National Collaborative Innovation Center, Chengdu, 610041, China; Institute of Psychiatry and Neuroscience, Xinxiang Key Laboratory of Protein Palmitoylation and Major Human Diseases, Henan Health Commission Key Laboratory of Gastrointestinal Cancer Prevention and Treatment, Xinxiang Medical University, Xinxiang, 453000, China. Electronic address: april13th@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kong</LastName><ForeName>Eryan</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>The Third Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, 453000, China; Institute of Psychiatry and Neuroscience, Xinxiang Key Laboratory of Protein Palmitoylation and Major Human Diseases, Henan Health Commission Key Laboratory of Gastrointestinal Cancer Prevention and Treatment, Xinxiang Medical University, Xinxiang, 453000, China. Electronic address: eykong2012@163.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Redox Biol</MedlineTA><NlmUniqueID>101605639</NlmUniqueID><ISSNLinking>2213-2317</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Angiogenesis</Keyword><Keyword MajorTopicYN="N">DC661</Keyword><Keyword MajorTopicYN="N">Gpx1</Keyword><Keyword MajorTopicYN="N">Oxygen-induced retinopathy</Keyword><Keyword MajorTopicYN="N">PPT1</Keyword><Keyword MajorTopicYN="N">S-Palmitoylation</Keyword></KeywordList><CoiStatement>Declaration of competing interest YDM, JLZ, and EYK is listed as inventor on pending patent covering the targeting of PPT-Gpx1 axis as intervention strategy for treating pathological angiogenesis. All other authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>18</Day><Hour>18</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>18</Day><Hour>18</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>18</Day><Hour>18</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39423458</ArticleId><ArticleId IdType="doi">10.1016/j.redox.2024.103376</ArticleId><ArticleId IdType="pii">S2213-2317(24)00354-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39423422</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1933-0693</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>18</Day></PubDate></JournalIssue><Title>Journal of neurosurgery</Title><ISOAbbreviation>J Neurosurg</ISOAbbreviation></Journal><ArticleTitle>Chordoma incidence, treatment, and survival in the 21st century: a population-based Ontario cohort study.</ArticleTitle><Pagination><StartPage>1</StartPage><EndPage>10</EndPage><MedlinePgn>1-10</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3171/2024.6.JNS24426</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">This study estimates the incidence, treatment patterns, and overall survival for patients with chordoma treated in Ontario.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A 17-year (2003-2019) population-based cohort study was conducted, including all patients in the Ontario Cancer Registry with histologically proven chordoma. Primary outcomes of interest were age-standardized annual incidence, overall survival, and rates of radiation therapy, chemotherapy, and open resection.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 208 patients were diagnosed with chordoma over the study period: 97 patients with skull base chordoma, 37 with mobile spine chordoma, and 65 with sacropelvic chordoma. A total of 133 patients were treated with either open or endoscopic surgery, of whom 99 were also treated with some form of radiation therapy. Across the 17-year study period, the average annual age-standardized incidence was 12.04 cases per 10 million (95% CI 9.31-14.78 cases per 10 million). There was no significant change in the annual incidence rate over the study period (average annual percent change 2.27, 95% CI -1.74 to 6.44; p = 0.25). The odds of receiving radiation therapy or chemotherapy significantly increased by 8% per year (95% CI 1%-16% per year, p = 0.036) over the study period. The odds of receiving open resection significantly decreased by 14% per year (95% CI 8%-20% per year, p &lt; 0.001). The odds of receiving endoscopic surgery among patients with skull base chordoma increased by 38% per year (95% CI 22%-60% per year, p &lt; 0.001), while the odds of patients receiving biopsy alone did not change significantly over the study period (p = 0.684). After diagnosis of chordoma, the 5-, 10-, and 15-year overall survival probabilities were 0.74 (95% CI 0.69-0.81), 0.58 (95% CI 0.51-0.67), and 0.48 (95% CI 0.40 to 0.59), respectively. There was no significant association between hazard of death and year of diagnosis (p = 0.126) or anatomical location (p = 0.712, skull base vs mobile spine chordoma; p = 0.518 skull base vs sacropelvic chordoma).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Chordoma is a rare disease with no significant change in the average annual incidence rate between 2003 to 2019. During this time, treatment with less invasive modalities increased, particularly for skull base chordoma. Overall survival exceeds 10 years for many patients, with no change in the hazard of death across the study period.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shakil</LastName><ForeName>Husain</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>1Department of Surgery, Division of Neurosurgery, University of Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>3Institute of Health Policy Management and Evaluation, University of Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malhotra</LastName><ForeName>Armaan K</ForeName><Initials>AK</Initials><AffiliationInfo><Affiliation>1Department of Surgery, Division of Neurosurgery, University of Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>3Institute of Health Policy Management and Evaluation, University of Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Essa</LastName><ForeName>Ahmad</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>2Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>4Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Landry</LastName><ForeName>Alexander P</ForeName><Initials>AP</Initials><AffiliationInfo><Affiliation>1Department of Surgery, Division of Neurosurgery, University of Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>6Krembil Research Institute, Toronto Western Hospital, Toronto, Ontario, Canada; and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suppiah</LastName><ForeName>Suganth</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>1Department of Surgery, Division of Neurosurgery, University of Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>6Krembil Research Institute, Toronto Western Hospital, Toronto, Ontario, Canada; and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sahgal</LastName><ForeName>Arjun</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>5Department of Radiation Oncology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dea</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>7Neurosurgical and Orthopedic Spine Program, Vancouver General Hospital, University of British Columbia, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zadeh</LastName><ForeName>Gelareh</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>1Department of Surgery, Division of Neurosurgery, University of Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>6Krembil Research Institute, Toronto Western Hospital, Toronto, Ontario, Canada; and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fehlings</LastName><ForeName>Michael G</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>1Department of Surgery, Division of Neurosurgery, University of Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>6Krembil Research Institute, Toronto Western Hospital, Toronto, Ontario, Canada; and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Witiw</LastName><ForeName>Christopher D</ForeName><Initials>CD</Initials><AffiliationInfo><Affiliation>1Department of Surgery, Division of Neurosurgery, University of Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>3Institute of Health Policy Management and Evaluation, University of Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilson</LastName><ForeName>Jefferson R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>1Department of Surgery, Division of Neurosurgery, University of Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>3Institute of Health Policy Management and Evaluation, University of Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosurg</MedlineTA><NlmUniqueID>0253357</NlmUniqueID><ISSNLinking>0022-3085</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">chordoma</Keyword><Keyword MajorTopicYN="N">cohort studies</Keyword><Keyword MajorTopicYN="N">epidemiology</Keyword><Keyword MajorTopicYN="N">incidence</Keyword><Keyword MajorTopicYN="N">spinal neoplasms</Keyword><Keyword MajorTopicYN="N">survival</Keyword><Keyword MajorTopicYN="N">tumor</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>18</Day><Hour>18</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>18</Day><Hour>18</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>2</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>6</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>18</Day><Hour>17</Hour><Minute>53</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39423422</ArticleId><ArticleId IdType="doi">10.3171/2024.6.JNS24426</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39423347</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>18</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2573-8348</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Cancer reports (Hoboken, N.J.)</Title><ISOAbbreviation>Cancer Rep (Hoboken)</ISOAbbreviation></Journal><ArticleTitle>Evaluating the Time Interval Between Symptoms Onset, Diagnosis, and Therapeutic Intervention in Lung Cancer: A Cross-Sectional Study in Southern Iran.</ArticleTitle><Pagination><StartPage>e70026</StartPage><MedlinePgn>e70026</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/cnr2.70026</ELocationID><Abstract><AbstractText Label="BACKGROUND AND AIM" NlmCategory="OBJECTIVE">Delay in diagnosis and treatment of lung cancer is thought to be a major cause of its poor outcomes. We evaluated the delays within the presentation to the initiation of diagnostic and therapeutic interventions amongst lung cancer patients in Southern Iran.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This cross-sectional study was conducted from March 2019 to March 2021. The data collected through interview included socio-demographic, medical and clinical findings, and the time intervals needed to visit physician, refer to specialist, request diagnostic procedures, reach diagnosis of lung cancer, and hospitalization.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Eighty-nine patients (58 males and 31 females) with a mean age of 61.01&#x2009;&#xb1;&#x2009;12.25&#x2009;years were included. The median time of symptom presentation and first physician visit interval was 25&#x2009;days. Sixty-five days were spent for requesting, performing, and evaluating the diagnostic procedures. The median interval between diagnosis and initiation of treatment was 16&#x2009;days. Totally, it took an average of 122&#x2009;days from the presentation to the definite diagnosis of lung cancer. Patient-, diagnosis-, and treatment-related delays were not significantly correlated with any of the demographic, socioeconomic, and clinical (disease stage, symptom) variables, as well as the diagnosis tool and the first physician who visited the patient (p&#x2009;&gt;&#x2009;0.05).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">There was a significant delay but relatively similar to other countries in the diagnosis and treatment of lung cancer patients in Southern Iran. The largest portion of delay could be attributed to the raising clinical suspicion in the physicians, referral for diagnostic assessments, and the diagnosis process.</AbstractText><CopyrightInformation>&#xa9; 2024 The Author(s). Cancer Reports published by Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Salehi</LastName><ForeName>Alireza</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of MPH, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rezvani</LastName><ForeName>Alireza</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Thoracic and Vascular Surgery Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fallahi</LastName><ForeName>Mohammad Javad</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Thoracic and Vascular Surgery Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gholamabbas</LastName><ForeName>Ghazal</ForeName><Initials>G</Initials><Identifier Source="ORCID">0009-0008-8749-1952</Identifier><AffiliationInfo><Affiliation>Shiraz Nephro-Urology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moayedfar</LastName><ForeName>Maryam</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Internal Medicine Department, Shiraz University of Medical Sciences, Shiraz, Iran.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cancer Rep (Hoboken)</MedlineTA><NlmUniqueID>101747728</NlmUniqueID><ISSNLinking>2573-8348</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008175" MajorTopicYN="Y">Lung Neoplasms</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007492" MajorTopicYN="N" Type="Geographic">Iran</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061665" MajorTopicYN="Y">Time-to-Treatment</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057210" MajorTopicYN="Y">Delayed Diagnosis</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055088" MajorTopicYN="N">Early Detection of Cancer</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Iran</Keyword><Keyword MajorTopicYN="N">diagnostic delay</Keyword><Keyword MajorTopicYN="N">lung neoplasms</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>18</Day><Hour>18</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>18</Day><Hour>18</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>7</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>2</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>18</Day><Hour>15</Hour><Minute>42</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39423347</ArticleId><ArticleId IdType="doi">10.1002/cnr2.70026</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>H. Sung, J. Ferlay, R. L. Siegel, et al., &#x201c;Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries,&#x201d; CA: A Cancer Journal for Clinicians 71, no. 3 (2021): 209&#x2013;249.</Citation></Reference><Reference><Citation>R. L. Siegel, K. D. Miller, and A. Jemal, &#x201c;Cancer Statistics, 2020,&#x201d; CA: A Cancer Journal for Clinicians 70, no. 1 (2020): 7&#x2013;30.</Citation></Reference><Reference><Citation>M. Ng, M. K. Freeman, T. D. Fleming, et al., &#x201c;Smoking Prevalence and Cigarette Consumption in 187 Countries, 1980&#x2010;2012,&#x201d; Journal of the American Medical Association 311, no. 2 (2014): 183&#x2013;192.</Citation></Reference><Reference><Citation>G. A. Giovino, S. A. Mirza, J. M. Samet, et al., &#x201c;Tobacco Use in 3 Billion Individuals From 16 Countries: An Analysis of Nationally Representative Cross&#x2010;Sectional Household Surveys,&#x201d; Lancet 380, no. 9842 (2012): 668&#x2013;679.</Citation></Reference><Reference><Citation>M. P. T. Kennedy, L. Cheyne, M. Darby, et al., &#x201c;Lung Cancer Stage&#x2010;Shift Following a Symptom Awareness Campaign,&#x201d; Thorax 73, no. 12 (2018): 1128&#x2013;1136.</Citation></Reference><Reference><Citation>L. Ironmonger, E. Ohuma, N. Ormiston&#x2010;Smith, C. Gildea, C. S. Thomson, and M. D. Peake, &#x201c;An Evaluation of the Impact of Large&#x2010;Scale Interventions to Raise Public Awareness of a Lung Cancer Symptom,&#x201d; British Journal of Cancer 112, no. 1 (2015): 207&#x2013;216.</Citation></Reference><Reference><Citation>The National Lung Screening Trial Research Team, &#x201c;Reduced Lung&#x2010;Cancer Mortality With Low&#x2010;Dose Computed Tomographic Screening,&#x201d; New England Journal of Medicine 365, no. 5 (2011): 395&#x2013;409.</Citation></Reference><Reference><Citation>H. De Koning, C. Van Der Aalst, K. Ten Haaf, and M. Oudkerk, &#x201c;PL02.05 Effects of Volume CT Lung Cancer Screening: Mortality Results of the NELSON Randomised&#x2010;Controlled Population Based Trial,&#x201d; Journal of Thoracic Oncology 13, no. 10 (2018): S185.</Citation></Reference><Reference><Citation>S. Smith, S. Fielding, P. Murchie, et al., &#x201c;Reducing the Time Before Consulting With Symptoms of Lung Cancer: A Randomised Controlled Trial in Primary Care,&#x201d; British Journal of General Practice 63, no. 606 (2013): e47&#x2013;e54.</Citation></Reference><Reference><Citation>J. D. Emery, S. R. Murray, F. M. Walter, et al., &#x201c;The Chest Australia Trial: A Randomised Controlled Trial of an Intervention to Increase Consultation Rates in Smokers at Risk of Lung Cancer,&#x201d; Thorax 74, no. 4 (2019): 362&#x2013;370.</Citation></Reference><Reference><Citation>Office for National Statistics, &#x201c;Cancer Survival in England: National Estimates for Patients Followed up to 2017,&#x201d; 2019, https://www.ons.gov.uk/releases/cancersurvivalinenglandadultstageatdiagnosisandchildhoodpatientsfollowedupto2017.</Citation></Reference><Reference><Citation>G. Gatta, L. Botta, S. Rossi, et al., &#x201c;Childhood Cancer Survival in Europe 1999&#x2010;2007: Results of EUROCARE&#x2010;5&#x2014;A Population&#x2010;Based Study,&#x201d; Lancet Oncology 15, no. 1 (2014): 35&#x2013;47.</Citation></Reference><Reference><Citation>L. Holmberg, F. Sandin, F. Bray, et al., &#x201c;National Comparisons of Lung Cancer Survival in England, Norway and Sweden 2001&#x2013;2004: Differences Occur Early in Follow&#x2010;Up,&#x201d; Thorax 65, no. 5 (2010): 436&#x2013;441.</Citation></Reference><Reference><Citation>W. J. Mackillop, &#x201c;Killing Time: The Consequences of Delays in Radiotherapy,&#x201d; Radiotherapy and Oncology 84, no. 1 (2007): 1&#x2013;4.</Citation></Reference><Reference><Citation>T. P. Hanna, W. D. King, S. Thibodeau, et al., &#x201c;Mortality Due to Cancer Treatment Delay: Systematic Review and Meta&#x2010;Analysis,&#x201d; BMJ 371 (2020): m4087.</Citation></Reference><Reference><Citation>T. R. Cushman, B. Jones, D. Akhavan, et al., &#x201c;The Effects of Time to Treatment Initiation for Patients With Non&#x2010;Small&#x2010;Cell Lung Cancer in the United States,&#x201d; Clinical Lung Cancer 22, no. 1 (2021): e84&#x2013;e97.</Citation></Reference><Reference><Citation>National Health Service, The NHS Cancer Plan: A Plan for Investment, a Plan for Reform (London, UK: Department of Health, 2000), https://www.thh.nhs.uk/documents/_Departments/Cancer/NHSCancerPlan.pdf.</Citation></Reference><Reference><Citation>Cancer Council Victoria, Optimal Care Pathway for People With Lung Cancer (Australia: Cancer Council Australia and Cancer Australia (Australian Government), 2016), https://www.cancer.org.au/assets/pdf/lung&#x2010;cancer&#x2010;optimal&#x2010;cancer&#x2010;care&#x2010;pathway.</Citation></Reference><Reference><Citation>R. G. Stirling, S. M. Evans, P. McLaughlin, et al., &#x201c;The Victorian Lung Cancer Registry Pilot: Improving the Quality of Lung Cancer Care Through the Use of a Disease Quality Registry,&#x201d; Lung 192, no. 5 (2014): 749&#x2013;758.</Citation></Reference><Reference><Citation>National Health Service, &#x201c;The Lung Clinical Expert Group: National Optimal Clinical Pathway for Suspected and Confirmed Lung Cancer: Referral to Treatment,&#x201d; 2017, https://www.lcnuk.org/sites/lcnuk.org/files/sites/default/files/NOLCPv3.pdf.</Citation></Reference><Reference><Citation>P. M. Ellis and R. Vandermeer, &#x201c;Delays in the Diagnosis of Lung Cancer,&#x201d; Journal of Thoracic Disease 3, no. 3 (2011): 183&#x2013;188.</Citation></Reference><Reference><Citation>T. E. Stinchcombe, F. C. Detterbeck, L. Lin, M. P. Rivera, and M. A. Socinski, &#x201c;Beliefs Among Physicians in the Diagnostic and Therapeutic Approach to Non&#x2010;Small Cell Lung Cancer,&#x201d; Journal of Thoracic Oncology 2, no. 9 (2007): 819&#x2013;826.</Citation></Reference><Reference><Citation>R. M. Vidaver, M. B. Shershneva, S. J. Hetzel, T. R. Holden, and T. C. Campbell, &#x201c;Typical Time to Treatment of Patients With Lung Cancer in a Multisite, US&#x2010;Based Study,&#x201d; Journal of Oncology Practice 12, no. 6 (2016): e643&#x2013;e653.</Citation></Reference><Reference><Citation>E. R. Salomaa, S. S&#xe4;llinen, H. Hiekkanen, and K. Liippo, &#x201c;Delays in the Diagnosis and Treatment of Lung Cancer,&#x201d; Chest 128, no. 4 (2005): 2282&#x2013;2288.</Citation></Reference><Reference><Citation>S. Vald&#xe9;s, E. Garc&#xed;a, H. P&#xe9;rez, and M. Hern&#xe1;ndez, &#x201c;Length of Diagnostic Delay in Patients With Non&#x2010;Small&#x2010;Cell Lung Cancer,&#x201d; MEDICC Review 12, no. 1 (2010): 29&#x2013;32.</Citation></Reference><Reference><Citation>H. Koyi, G. Hillerdal, and E. Brand&#xe9;n, &#x201c;Patient's and Doctors' Delays in the Diagnosis of Chest Tumors,&#x201d; Lung Cancer 35, no. 1 (2002): 53&#x2013;57.</Citation></Reference><Reference><Citation>M. Bjerager, T. Palshof, R. Dahl, P. Vedsted, and F. Olesen, &#x201c;Delay in Diagnosis of Lung Cancer in General Practice,&#x201d; British Journal of General Practice 56, no. 532 (2006): 863&#x2013;868.</Citation></Reference><Reference><Citation>A. S. Yurdakul, C. Kocat&#xfc;rk, H. Bayiz, et al., &#x201c;Patient and Physician Delay in the Diagnosis and Treatment of Non&#x2010;Small Cell Lung Cancer in Turkey,&#x201d; Cancer Epidemiology 39, no. 2 (2015): 216&#x2013;221.</Citation></Reference><Reference><Citation>S. M. Smith, N. C. Campbell, U. MacLeod, et al., &#x201c;Factors Contributing to the Time Taken to Consult With Symptoms of Lung Cancer: A Cross&#x2010;Sectional Study,&#x201d; Thorax 64, no. 6 (2009): 523&#x2013;531.</Citation></Reference><Reference><Citation>J. Kotecha, A. Clark, M. Burton, et al., &#x201c;Evaluating the Delay Prior to Primary Care Presentation in Patients With Lung Cancer: A Cohort Study,&#x201d; BJGP Open 5, no. 2 (2021): BJGPO.2020.0130.</Citation></Reference><Reference><Citation>T. B. Y. Ozl&#xfc;, F. &#xd6;ztuna, and C. Gamze, &#x201c;How Long the Diagnostic and Therapeutic Process Takes in Lung Cancers,&#x201d; Tuberc Thorax 50 (2002): 288&#x2013;291.</Citation></Reference><Reference><Citation>The Lung Cancer Working Party of the British Thoracic Society Standards of Care Committee, &#x201c;BTS Recommendations to Respiratory Physicians for Organising the Care of Patients With Lung Cancer,&#x201d; Thorax 53, no. Suppl 1 (1998): S1&#x2013;S8.</Citation></Reference><Reference><Citation>J. K. Olsson, E. M. Schultz, and M. K. Gould, &#x201c;Timeliness of Care in Patients With Lung Cancer: A Systematic Review,&#x201d; Thorax 64, no. 9 (2009): 749&#x2013;756.</Citation></Reference><Reference><Citation>E. Sulu, O. Tasolar, H. Berk Takir, L. Yagci Tuncer, Z. Karakurt, and A. Yilmaz, &#x201c;Delays in the Diagnosis and Treatment of Non&#x2010;Small&#x2010;Cell Lung Cancer,&#x201d; Tumori 97, no. 6 (2011): 693&#x2013;697.</Citation></Reference><Reference><Citation>G. Lyratzopoulos, G. A. Abel, S. McPhail, R. D. Neal, and G. P. Rubin, &#x201c;Measures of Promptness of Cancer Diagnosis in Primary Care: Secondary Analysis of National Audit Data on Patients With 18 Common and Rarer Cancers,&#x201d; British Journal of Cancer 108, no. 3 (2013): 686&#x2013;690.</Citation></Reference><Reference><Citation>P. Baughan, B. O'Neill, and E. Fletcher, &#x201c;Auditing the Diagnosis of Cancer in Primary Care: The Experience in Scotland,&#x201d; British Journal of Cancer 101, no. Suppl 2 (2009): S87&#x2013;S91.</Citation></Reference><Reference><Citation>D. M. Tromp, X. D. Brouha, G. J. Hordijk, J. A. Winnubst, and J. R. de Leeuw, &#x201c;Patient Factors Associated With Delay in Primary Care Among Patients With Head and Neck Carcinoma: A Case&#x2010;Series Analysis,&#x201d; Family Practice 22, no. 5 (2005): 554&#x2013;559.</Citation></Reference><Reference><Citation>H. A. Hamann, J. S. Ostroff, E. G. Marks, D. E. Gerber, J. H. Schiller, and S. J. Lee, &#x201c;Stigma Among Patients With Lung Cancer: A Patient&#x2010;Reported Measurement Model,&#x201d; Psycho&#x2010;Oncology 23, no. 1 (2014): 81&#x2013;92.</Citation></Reference><Reference><Citation>B. D. Nicholson, D. Mant, R. D. Neal, et al., &#x201c;International Variation in Adherence to Referral Guidelines for Suspected Cancer: A Secondary Analysis of Survey Data,&#x201d; British Journal of General Practice 66, no. 643 (2016): e106&#x2013;e113.</Citation></Reference><Reference><Citation>J. P. M. P. Rachtan, J. Rachtan, and M. Pawlicki, &#x201c;Przyczyny op&#xf3;&#x17a;nienia w Leczeniu Chorych na drobnokom&#xf3;rkowego Raka p&#x142;uca (Causes of Delayed Treatment of Patients With Small Cell Lung Cancer),&#x201d; Pneumonologia Polska 58, no. 11&#x2013;12 (1990): 615&#x2013;619.</Citation></Reference><Reference><Citation>H. Hardardottir, U. A. Valdimarsdottir, T. Gudbjartsson, et al., &#x201c;Fast Diagnostic Track for Suspected Lung Cancer: A Patient Centered Approach,&#x201d; L&#xe6;knabla&#x111;i&#x111; 103, no. 4 (2017): 171&#x2013;177.</Citation></Reference><Reference><Citation>P. Pradere, C. Caramella, F. B. Salem, et al., &#x201c;A Patient&#x2010;Centered Model of Fast&#x2010;Track Lung Cancer Diagnosis,&#x201d; Clinical Lung Cancer 24, no. 5 (2023): 453&#x2013;458.</Citation></Reference><Reference><Citation>M. J. Fallahi, A. Baghaei, A. Rezvani, et al., &#x201c;Lung Cancer Registry and Monitoring: Feasibility Study and Application (Fars Lung Cancer Registry Project),&#x201d; Journal of Research in Medical Sciences: The Official Journal of Isfahan University of Medical Sciences 28 (2023): 48.</Citation></Reference><Reference><Citation>F. C. Abrao, I. R. L. B. D. Abreu, R. O. Rocha, F. D. Munhoz, J. H. G. Rodrigues, and R. N. Younes, &#x201c;Impact of the Delay to Start Treatment in Patients With Lung Cancer Treated in a Densely Populated Area of Brazil,&#x201d; Clinics 72 (2017): 675&#x2013;680.</Citation></Reference><Reference><Citation>J. Billing and F. Wells, &#x201c;Delays in the Diagnosis and Surgical Treatment of Lung Cancer,&#x201d; Thorax 51, no. 9 (1996): 903&#x2013;906.</Citation></Reference><Reference><Citation>F. Barata, P. Fidalgo, S. Figueiredo, F. S. Tonin, and F. Duarte&#x2010;Ramos, &#x201c;Limitations and Perceived Delays for Diagnosis and Staging of Lung Cancer in Portugal: A Nationwide Survey Analysis,&#x201d; PLoS One 16, no. 6 (2021): e0252529.</Citation></Reference><Reference><Citation>L. F. Forrest, J. Adams, G. Rubin, and M. White, &#x201c;The Role of Receipt and Timeliness of Treatment in Socioeconomic Inequalities in Lung Cancer Survival: Population&#x2010;Based, Data&#x2010;Linkage Study,&#x201d; Thorax 70, no. 2 (2015): 138&#x2013;145.</Citation></Reference><Reference><Citation>A. Ansar, V. Lewis, C. F. McDonald, C. Liu, and M. A. Rahman, &#x201c;Defining Timeliness in Care for Patients With Lung Cancer: A Scoping Review,&#x201d; BMJ Open 12, no. 4 (2022): e056895.</Citation></Reference><Reference><Citation>D. J. Wake, F. W. Gibb, P. Kar, et al., &#x201c;Endocrinology in the Time of COVID&#x2010;19: Remodelling Diabetes Services and Emerging Innovation,&#x201d; European Journal of Endocrinology 183, no. 2 (2020): G67&#x2013;G77.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39423343</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1754-9485</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>18</Day></PubDate></JournalIssue><Title>Journal of medical imaging and radiation oncology</Title><ISOAbbreviation>J Med Imaging Radiat Oncol</ISOAbbreviation></Journal><ArticleTitle>Optimising PTV margins in oesophageal cancer radiotherapy: A&#xa0;modern radiotherapy planning, treatment delivery and verification approach - A single institutional analysis.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1111/1754-9485.13738</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Radiotherapy plays a key role in the multidisciplinary management of oesophageal cancers across neoadjuvant, definitive and palliative settings. Improved precision in radiotherapy planning and delivery techniques have allowed treating disease with tighter margins reducing toxicity. In this study, we examine the appropriateness of current practice in defining the planning target volume (PTV).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This is a single institutional retrospective study of patients who received radiotherapy for oesophageal cancers using volumetric modulated arc therapy (VMAT) during 2020. All cone-beam computerised tomography (CBCT) scans were reviewed to assess whether PTV expansions appropriately accounted for tumour motion and interfractional variation.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the 27 patients, 2 (7%), 5 (19%) and 20 (74%) had cervical, thoracic and distal/gastro-oesophageal junction (GOJ) disease, respectively. 16 (59%) had adenocarcinoma and 9 (33%) had squamous cell carcinoma. 9 of 20 distal/GOJ patients were planned and treated according to the institutional stomach filling protocol. 521/528 (98.7%) CBCTs demonstrated adequate target coverage. Cervical, thoracic and GOJ regions demonstrated adequate target coverage in 57/58, 96/97 and 368/373 CBCTs with median PTV expansions of 5, 7 and 7&#x2009;mm, respectively. In four patients with GOJ disease, CBCT review identified five episodes where the target volume was insufficiently covered during the treatment course.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">In this single institutional retrospective study, for the vast majority of patients, our institutional practice of defining PTV margins achieved satisfactory target treatment. The interfractional variations observed in patients with GOJ tumours due to target motion and variable gastric volume, highlights the role of further refinements to motion management techniques in this cohort.</AbstractText><CopyrightInformation>&#xa9; 2024 Royal Australian and New Zealand College of Radiologists.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mitchell</LastName><ForeName>Jack</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-3134-694X</Identifier><AffiliationInfo><Affiliation>Princess Alexandra Hospital, Brisbane, Queensland, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Campbell</LastName><ForeName>Amelia</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Princess Alexandra Hospital, Brisbane, Queensland, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Ming</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Princess Alexandra Hospital, Brisbane, Queensland, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harvey</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Princess Alexandra Hospital, Brisbane, Queensland, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Queensland, St Lucia, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mai</LastName><ForeName>Gang Tao</ForeName><Initials>GT</Initials><AffiliationInfo><Affiliation>Princess Alexandra Hospital, Brisbane, Queensland, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Queensland, St Lucia, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Yoo Young</ForeName><Initials>YY</Initials><AffiliationInfo><Affiliation>Princess Alexandra Hospital, Brisbane, Queensland, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Queensland, St Lucia, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Australia</Country><MedlineTA>J Med Imaging Radiat Oncol</MedlineTA><NlmUniqueID>101469340</NlmUniqueID><ISSNLinking>1754-9477</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">radiation oncology</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>18</Day><Hour>18</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>18</Day><Hour>18</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>11</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>7</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>18</Day><Hour>15</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39423343</ArticleId><ArticleId IdType="doi">10.1111/1754-9485.13738</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>https://www.canceraustralia.gov.au/cancer&#x2010;types/oesophageal&#x2010;cancer/statistics [Accessed 23 Mar 2024].</Citation></Reference><Reference><Citation>https://ncci.canceraustralia.gov.au/diagnosis/cancer&#x2010;incidence/cancer&#x2010;incidence [Accessed 23 Mar 2024].</Citation></Reference><Reference><Citation>Roos CTG, Faiz Z, Visser S et&#xa0;al. A comprehensive motion analysis &#x2013; consequences for high precision image&#x2010;guided radiotherapy of esophageal cancer patients. Acta Oncol 2021; 60: 277&#x2013;284.</Citation></Reference><Reference><Citation>Lesueur P, Servagi&#x2010;Vernat S. Definition of accurate planning target volume margins for esophageal cancer radiotherapy. Cancer/Radiotherapie 2016; 20: 651&#x2013;656.</Citation></Reference><Reference><Citation>Halperin EC, Brady LW, Wazer DE, Perez CA. Perez and Brady's Principles and Practice of Radiation Oncology, 6th edn. Wolters Kluwer Health/Lippincott Williams &amp; Wilkins, Philadelphia, PA, 2013; 2448 p.</Citation></Reference><Reference><Citation>Chandra A, Guerrero TM, Liu HH et&#xa0;al. Feasibility of using intensity&#x2010;modulated radiotherapy to improve lung sparing in treatment planning for distal esophageal cancer. Radiother Oncol 2005; 77: 247&#x2013;253.</Citation></Reference><Reference><Citation>Wu AJ, Bosch WR, Chang DT et&#xa0;al. Expert consensus contouring guidelines for intensity modulated radiation therapy in esophageal and gastroesophageal junction cancer. Int J Radiat Oncol Biol Phys 2015; 92: 911&#x2013;920.</Citation></Reference><Reference><Citation>Han C, Schiffner DC, Schultheiss TE, Chen YJ, Liu A, Wong JY. Residual setup errors and dose variations with less&#x2010;than&#x2010;daily image guided patient setup in external beam radiotherapy for esophageal cancer. Radiother Oncol 2012; 102: 309&#x2013;314.</Citation></Reference><Reference><Citation>van Hagen P, Hulshof MCCM, van Lanschot JJB et&#xa0;al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012; 366: 2074&#x2013;2084.</Citation></Reference><Reference><Citation>Herskovic A, Martz K, Al&#x2010;Sarraf M et&#xa0;al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 1992; 326: 1593&#x2013;1598.</Citation></Reference><Reference><Citation>Nabavizadeh N, Elliott DA, Chen Y et&#xa0;al. Image Guided Radiation Therapy (IGRT) practice patterns and IGRT's impact on workflow and treatment planning: Results from a national survey of American Society for Radiation Oncology Members. Int J Radiat Oncol Biol Phys 2016; 94: 850&#x2010;857.</Citation></Reference><Reference><Citation>Uhlenhopp DJ, Then EO, Sunkara T, Gaduputi V. Epidemiology of esophageal cancer: update in global trends, etiology and risk factors. Clin J Gastroenterol 2020; 13: 1010&#x2013;1021.</Citation></Reference><Reference><Citation>Morgan E, Soerjomataram I, Rumgay H et&#xa0;al. The global landscape of esophageal squamous cell carcinoma and esophageal adenocarcinoma incidence and mortality in 2020 and projections to 2040: new estimates from GLOBOCAN 2020. Gastroenterology 2022; 163: 649&#x2013;658.e2.</Citation></Reference><Reference><Citation>Chen X, Lu H, Tai A, Johnstone C, Gore E, Li XA. Determination of internal target volume for radiation treatment planning of esophageal cancer by using 4&#x2010;dimensional computed tomography (4DCT). Int J Radiat Oncol Biol Phys 2014; 90: 102&#x2013;109.</Citation></Reference><Reference><Citation>Jin P, Hulshof MCCM, De Jong R, Van Hooft JE, Bel A, Alderliesten T. Quantification of respiration&#x2010;induced esophageal tumor motion using fiducial markers and four&#x2010;dimensional computed tomography. Radiother Oncol 2016; 118: 492&#x2013;497.</Citation></Reference><Reference><Citation>Lee SL, Bassetti M, Meijer GJ, Mook S. Review of MR&#x2010;guided radiotherapy for esophageal cancer. Front Oncol 2021; 11. https://doi.org/10.3389/fonc.2021.628009.</Citation></Reference><Reference><Citation>Lee SL, Mahler P, Olson S et&#xa0;al. Reduction of cardiac dose using respiratory&#x2010;gated MR&#x2010;linac plans for gastro&#x2010;esophageal junction cancer. Med Dosim 2021; 46: 152&#x2013;156.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39423328</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1473-558X</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>01</Day></PubDate></JournalIssue><Title>Neuroreport</Title><ISOAbbreviation>Neuroreport</ISOAbbreviation></Journal><ArticleTitle>Sodium valproate ablates ferroptosis in kainic acid-induced epileptic seizure via suppressing lysyl oxidase.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1097/WNR.0000000000002103</ELocationID><Abstract><AbstractText>The objective of this study is to explore whether sodium valproate (VPA) alleviates epileptic seizures via suppressing lysyl oxidase (Lox)-mediated ferroptosis. Epileptic seizure mouse model was prepared via intrahippocampal injection of kainic acid (250 ng/&#x3bc;l). After treatment with kainic acid, VPA was injected intraperitoneally by the dose of 250 mg/kg twice daily for 4 days. Ferroptosis-associated indices including lipid peroxides (LPO) level and Ptgs2 mRNA in hippocampal tissue samples were detected. Additionally, effects of VPA on Lox mRNA and enzymatic activity were assessed by quantitative real-time PCR and a commercial kit, respectively. Neuronal survival was assessed by Nissl staining. In kainic acid-induced epileptic seizure mouse model, VPA significantly suppressed LPO level and Ptgs2 mRNA and the suppression of ferroptosis was positively correlated with its anti-seizure effect. Lox mRNA and enzymatic activity were also found to decrease in hippocampus of epileptic seizure mice after VPA treatment. Furthermore, overexpression of Lox via adeno-associated virus infection remarkably abrogated the inhibitory effect of VPA on ferroptosis and neuronal impairment together with its anti-seizure effect. VPA suppresses Lox-mediated ferroptosis process, which can provide the explanation for its anti-seizure property.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 Wolters Kluwer Health, Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Qin</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital Central South University.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Clinical Pharmacology and Department of Engineering Research Center of Applied Technology of Pharmacogenomics of Ministry of Education, Central South University, Changsha.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Trials Center, The Affiliated Hospital of Guizhou Medical University, Guiyang.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Yu-Han</ForeName><Initials>YH</Initials><AffiliationInfo><Affiliation>Department of Intensive Care Medicine, Xiangya Hospital Central South University, Changsha.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Qiu-Qi</ForeName><Initials>QQ</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital Central South University.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Clinical Pharmacology and Department of Engineering Research Center of Applied Technology of Pharmacogenomics of Ministry of Education, Central South University, Changsha.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jia</LastName><ForeName>Ji-Ning</ForeName><Initials>JN</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital Central South University.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Clinical Pharmacology and Department of Engineering Research Center of Applied Technology of Pharmacogenomics of Ministry of Education, Central South University, Changsha.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Zhao-Qian</ForeName><Initials>ZQ</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital Central South University.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Clinical Pharmacology and Department of Engineering Research Center of Applied Technology of Pharmacogenomics of Ministry of Education, Central South University, Changsha.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Hong-Hao</ForeName><Initials>HH</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital Central South University.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Clinical Pharmacology and Department of Engineering Research Center of Applied Technology of Pharmacogenomics of Ministry of Education, Central South University, Changsha.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Xin-Yu</ForeName><Initials>XY</Initials><AffiliationInfo><Affiliation>Department of Neurology, The First Affiliated Hospital of Kangda College of Nanjing Medical University.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, The Affiliated Lianyungang Hospital of Xuzhou Medical University, Lianyungang.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>Wei-Lin</ForeName><Initials>WL</Initials><AffiliationInfo><Affiliation>Institute of Cancer Neuroscience, Department of Medical Frontier Innovation Research Center, The First Hospital of Lanzhou University, The First Clinical Medical College of Lanzhou University, Lanzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mao</LastName><ForeName>Xiao-Yuan</ForeName><Initials>XY</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital Central South University.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Clinical Pharmacology and Department of Engineering Research Center of Applied Technology of Pharmacogenomics of Ministry of Education, Central South University, Changsha.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Neuroreport</MedlineTA><NlmUniqueID>9100935</NlmUniqueID><ISSNLinking>0959-4965</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>18</Day><Hour>18</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>18</Day><Hour>18</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>18</Day><Hour>14</Hour><Minute>53</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39423328</ArticleId><ArticleId IdType="doi">10.1097/WNR.0000000000002103</ArticleId><ArticleId IdType="pii">00001756-990000000-00292</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Peterson GM, Naunton M. Valproate: a simple chemical with so much to offer. J Clin Pharm Ther 2005; 30:417&#x2013;421.</Citation></Reference><Reference><Citation>Romoli M, Mazzocchetti P, D'Alonzo R, Siliquini S, Rinaldi VE, Verrotti A, et al. Valproic acid and epilepsy: from molecular mechanisms to clinical evidences. Curr Neuropharmacol 2019; 17:926&#x2013;946.</Citation></Reference><Reference><Citation>Singh D, Gupta S, Verma I, Morsy MA, Nair AB, Ahmed AF. Hidden pharmacological activities of valproic acid: a new insight. Biomed Pharmacother 2021; 142:112021.</Citation></Reference><Reference><Citation>Chen X, Wang H, Zhou M, Li X, Fang Z, Gao H, et al. Valproic acid attenuates traumatic brain injury-induced inflammation in vivo: involvement of autophagy and the Nrf2/Are signaling pathway. Front Mol Neurosci 2018; 11:117.</Citation></Reference><Reference><Citation>Ahlatci A, Yildizhan K, T&#xfc;l&#xfc;ce Y, Bekta&#x15f; M. Valproic acid attenuated PTZ-induced oxidative stress, inflammation, and apoptosis in the SH-SY5Y cells via modulating the TRPM2 channel. Neurotox Res 2022; 40:1979&#x2013;1988.</Citation></Reference><Reference><Citation>Jiang X, Stockwell BR, Conrad M. Ferroptosis: mechanisms, biology and role in disease. Nat Rev Mol Cell Biol 2021; 22:266&#x2013;282.</Citation></Reference><Reference><Citation>Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 2012; 149:1060&#x2013;1072.</Citation></Reference><Reference><Citation>Chen KN, Guan Q-W, Yin X-X, Wang Z-J, Zhou H-H, Mao X-Y. Ferrostatin-1 obviates seizures and associated cognitive deficits in ferric chloride-induced posttraumatic epilepsy via suppressing ferroptosis. Free Radic Biol Med 2022; 179:109&#x2013;118.</Citation></Reference><Reference><Citation>Mao XY, Zhou H-H, Jin W-L. Ferroptosis induction in pentylenetetrazole kindling and pilocarpine-induced epileptic seizures in mice. Front Neurosci 2019; 13:721.</Citation></Reference><Reference><Citation>Mao X, Wang X, Jin M, Li Q, Jia J, Li M, et al. Critical involvement of lysyl oxidase in seizure-induced neuronal damage through ERK-Alox5-dependent ferroptosis and its therapeutic implications. Acta Pharm Sin B 2022; 12:3513&#x2013;3528.</Citation></Reference><Reference><Citation>Yang N, Zhang K, Guan Q-W, Wang Z-J, Chen K-N, Mao X-Y. D-penicillamine reveals the amelioration of seizure-induced neuronal injury via inhibiting Aqp11-dependent ferroptosis. Antioxidants (Basel) 2022; 11:1602.</Citation></Reference><Reference><Citation>Wang Q, Ding S-L, Li Y, Royall J, Feng D, Lesnar P, et al. The Allen Mouse Brain Common Coordinate Framework: A 3D reference atlas. Cell 2020; 181:936&#x2013;953.e20.</Citation></Reference><Reference><Citation>Kay HY, Greene DL, Kang S, Kosenko A, Hoshi N. M-current preservation contributes to anticonvulsant effects of valproic acid. J Clin Invest 2015; 125:3904&#x2013;3914.</Citation></Reference><Reference><Citation>Gao F, Zhao Y, Zhang B, Xiao C, Sun Z, Gao Y, Dou X. Suppression of lncRNA Gm47283 attenuates myocardial infarction via miR-706/Ptgs2/ferroptosis axis. Bioengineered 2022; 13:10786&#x2013;10802.</Citation></Reference><Reference><Citation>Kesner RP, Lee I, Gilbert P. A behavioral assessment of hippocampal function based on a subregional analysis. Rev Neurosci 2004; 15:333&#x2013;351.</Citation></Reference><Reference><Citation>Mao C, Liu X, Zhang Y, Lei G, Yan Y, Lee H, et al. DHODH-mediated ferroptosis defence is a targetable vulnerability in cancer. Nature 2021; 593:586&#x2013;590.</Citation></Reference><Reference><Citation>Bao WD, Pang P, Zhou X-T, Hu F, Xiong W, Chen K, et al. Loss of ferroportin induces memory impairment by promoting ferroptosis in Alzheimer&#x2019;s disease. Cell Death Differ 2021; 28:1548&#x2013;1562.</Citation></Reference><Reference><Citation>Li Y, Ran Q, Duan Q, Jin J, Wang Y, Yu L, et al. 7-Dehydrocholesterol dictates ferroptosis sensitivity. Nature 2024; 626:411&#x2013;418.</Citation></Reference><Reference><Citation>Jiang T, Xiao Y, Zhou J, Luo Z, Yu L, Liao Q, et al. Arbutin alleviates fatty liver by inhibiting ferroptosis via FTO/SLC7A11 pathway. Redox Biol 2023; 68:102963.</Citation></Reference><Reference><Citation>Petrillo S, Pietrafusa N, Trivisano M, Calabrese C, Saura F, Gallo MG, et al. Imbalance of systemic redox biomarkers in children with epilepsy: role of ferroptosis. Antioxidants (Basel) 2021; 10:1267.</Citation></Reference><Reference><Citation>Jiang L, Kon N, Li T, Wang S-J, Su T, Hibshoosh H, et al. Ferroptosis as a p53-mediated activity during tumour suppression. Nature 2015; 520:57&#x2013;62.</Citation></Reference><Reference><Citation>Li Y, Li K, Zhao W, Wang H, Xue X, Chen X, et al. VPA improves ferroptosis in tubular epithelial cells after cisplatin-induced acute kidney injury. Front Pharmacol 2023; 14:1147772.</Citation></Reference><Reference><Citation>Kong Q, Li F, Sun K, Sun X, Ma J. Valproic acid ameliorates cauda equina injury by suppressing HDAC2-mediated ferroptosis. CNS Neurosci Ther 2024; 30:e14524.</Citation></Reference><Reference><Citation>Yang N, Cao D-F, Yin X-X, Zhou H-H, Mao X-Y. Lysyl oxidases: emerging biomarkers and therapeutic targets for various diseases. Biomed Pharmacother 2020; 131:110791.</Citation></Reference><Reference><Citation>Mart&#xed;nez-Revelles S, Garc&#xed;a-Redondo AB, Avenda&#xf1;o MS, Varona S, Palao T, Orriols M, et al. Lysyl oxidase induces vascular oxidative stress and contributes to arterial stiffness and abnormal elastin structure in hypertension: role of p38MAPK. Antioxid Redox Signal 2017; 27:379&#x2013;397.</Citation></Reference><Reference><Citation>Chandrakumar S, Santiago Tierno I, Agarwal M, Lessieur EM, Du Y, Tang J, et al. Mechanical regulation of retinal vascular inflammation and degeneration in diabetes. Diabetes 2024; 73:280&#x2013;291.</Citation></Reference><Reference><Citation>Chen KN, Peng Q-L, Cao D-F, Wang Z-J, Zhang K, Zhou X-Y, et al. Inhibition of lysyl oxidase by pharmacological intervention and genetic manipulation alleviates epilepsy-associated cognitive disorder. Brain Res Bull 2024; 210:110928.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39423314</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1473-5741</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>16</Day></PubDate></JournalIssue><Title>Anti-cancer drugs</Title><ISOAbbreviation>Anticancer Drugs</ISOAbbreviation></Journal><ArticleTitle>SMAC mimetic BV6 acts in synergy with mTOR inhibitor to increase cisplatin sensitivity in ovarian cancer.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1097/CAD.0000000000001664</ELocationID><Abstract><AbstractText>The objective of this study is to observe the antitumor efficacy of the second mitochondria-derived activator of caspases (SMAC) mimetic bivalent smac mimetic (BV6) in combination with target of rapamycin (mTOR) inhibitor on DDP (cisplatin) sensitivity. Ovarian cancer cells were exposed to cisplatin, BV6, DDP + BV6, and DDP + BV6 + mTOR inhibitor Rapamycin. Using proteomics and bioinformatics, protein expression profiles in ovarian cancer were determined. Bagg Albino color nude mice were treated with DDP or BV6 alone or in combination, or BV6 + DDP + Rapamycin. The effects of different treatments on ovarian cancer cells and tumor growth were evaluated in vivo and in vitro. Proteomics and bioinformatics analysis revealed significant changes of protein kinase (AKT)/mTOR pathway. Consistently, western blot data indicated that AKT/mTOR axis was gradually activated in BV6-treated ovarian cancer cells and attenuated the cytotoxic effect of BV6. Functional assays showed that DDP or BV6 treatment alone significantly enhanced the sensitivity and inhibited the migration of ovarian cancer cells, but without any synergistic effects. In addition, combination with BV6 and mTOR inhibitor Rapamycin significantly decreased cell viability and inhibited migration of ovarian cancer cells exposed to DDP. Consistently, the xenograft model showed that co-treatment with Rapamycin with BV6 had significantly suppressed tumor growth and metastasis. Our study demonstrated that SMAC analogue BV6 exhibits a strong anticancer effect on ovarian cancer in vitro and in vivo. Combination with Rapamycin overcomes the activation of mTOR pathway by BV6 and increases the chemosensitivity to DDP. These data suggest a potential application of triple combination with DDP + BV6 + Rapamycin in clinical management of ovarian cancer.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 Wolters Kluwer Health, Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Qi</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Gynecological Oncology, Tianjin Central Hospital of Obstetrics and Gynecology, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Hong</ForeName><Initials>H</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Anticancer Drugs</MedlineTA><NlmUniqueID>9100823</NlmUniqueID><ISSNLinking>0959-4973</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>18</Day><Hour>18</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>18</Day><Hour>18</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>18</Day><Hour>14</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39423314</ArticleId><ArticleId IdType="doi">10.1097/CAD.0000000000001664</ArticleId><ArticleId IdType="pii">00001813-990000000-00329</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lemma S, Perrone AM, De Iaco P, Gasparre G, Kurelac I. Current methodologies to detect circulating tumor cells: a focus on ovarian cancer. Am J Cancer Res 2021; 11:4111&#x2013;4126.</Citation></Reference><Reference><Citation>Lecointre L, Velten M, Lodi M, Saadeh R, Lavou&#xe9; V, Ouldamer L, et al. Impact of neoadjuvant chemotherapy cycles on survival of patients with advanced ovarian cancer: a French national multicenter study (FRANCOGYN). Eur J Obstet Gynecol Reprod Biol 2020; 245:64&#x2013;72.</Citation></Reference><Reference><Citation>Karimnia N, Wilson AL, Green E, Matthews A, Jobling TW, Plebanski M, et al. Chemoresistance is mediated by ovarian cancer leader cells in vitro. J Exp Clin Cancer Res 2021; 40:276.</Citation></Reference><Reference><Citation>Tendulkar S, Dodamani S. Chemoresistance in ovarian cancer: prospects for new drugs. Anticancer Agents Med Chem 2021; 21:668&#x2013;678.</Citation></Reference><Reference><Citation>Rada M, Nallanthighal S, Cha J, Ryan K, Sage J, Eldred C, et al. Inhibitor of apoptosis proteins (IAPs) mediate collagen type XI alpha 1-driven cisplatin resistance in ovarian cancer. Oncogene 2018; 37:4809&#x2013;4820.</Citation></Reference><Reference><Citation>Noonan AM, Bunch KP, Chen J-Q, Herrmann MA, Lee J-M, Kohn EC, et al. Pharmacodynamic markers and clinical results from the phase 2 study of the SMAC mimetic birinapant in women with relapsed platinum-resistant or -refractory epithelial ovarian cancer. Cancer 2016; 122:588&#x2013;597.</Citation></Reference><Reference><Citation>Du C, Fang M, Li Y, Li L, Wang X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 2000; 102:33&#x2013;42.</Citation></Reference><Reference><Citation>Hernandez LF, Dull AB, Korrapati S, Annunziata CM. Smac-mimetic enhances antitumor effect of standard chemotherapy in ovarian cancer models via Caspase 8-independent mechanism. Cell Death Discov 2021; 7:134.</Citation></Reference><Reference><Citation>Li BX, Wang H-B, Qiu M-Z, Luo Q-Y, Yi H-J, Yan X-L, et al. Novel smac mimetic APG-1387 elicits ovarian cancer cell killing through TNF-alpha, Ripoptosome and autophagy mediated cell death pathway. J Exp Clin Cancer Res 2018; 37:53.</Citation></Reference><Reference><Citation>Garg G, Vangveravong S, Zeng C, Collins L, Hornick M, et al. Conjugation to a SMAC mimetic potentiates sigma-2 ligand induced tumor cell death in ovarian cancer. Mol Cancer 2014; 13:50.</Citation></Reference><Reference><Citation>Rettinger E, Glatthaar A, Abhari BA, Oelsner S, Pfirrmann V, Huenecke S, et al. SMAC mimetic BV6 enables sensitization of resistant tumor cells but also affects cytokine-induced killer (CIK) cells: a potential challenge for combination therapy. Front Pediatr 2014; 2:75.</Citation></Reference><Reference><Citation>Weng H, Feng X, Lan Y, Zheng Z. TCP1 regulates PI3K/AKT/mTOR signaling pathway to promote proliferation of ovarian cancer cells. J Ovarian Res 2021; 14:82.</Citation></Reference><Reference><Citation>Ma J, Liu L, Ling Y, Zheng J. Polypeptide LTX-315 reverses the cisplatin chemoresistance of ovarian cancer cells via regulating Beclin-1/PI3K/mTOR signaling pathway. J Biochem Mol Toxicol 2021; 35:e22853.</Citation></Reference><Reference><Citation>Zhang X, Qin T, Zhu Z, Hong F, Xu Y, Zhang X, et al. Ivermectin augments the in vitro and in vivo efficacy of cisplatin in epithelial ovarian cancer by suppressing Akt/mTOR signaling. Am J Med Sci 2020; 359:123&#x2013;129.</Citation></Reference><Reference><Citation>El-Kott AF, Shati AA, Al-Kahtani MA, Alqahtani S. Acylated ghrelin renders chemosensitive ovarian cancer cells resistant to cisplatin chemotherapy via activation of the PI3K/Akt/mTOR survival pathway. Anal Cell Pathol (Amst) 2019; 2019:9627810.</Citation></Reference><Reference><Citation>Hermida-Prado F, Xie Y, Sherman S, Nagy Z, Russo D, Akhshi T, et al. Endocrine therapy synergizes with SMAC mimetics to potentiate antigen presentation and tumor regression in hormone receptor-positive breast cancer. Cancer Res 2023; 83:3284&#x2013;3304.</Citation></Reference><Reference><Citation>Dmello RS, Palmieri M, Thilakasiri PS, Doughty L, Nero TL, Poh AR, et al. Combination of bazedoxifene with chemotherapy and SMAC-mimetics for the treatment of colorectal cancer. Cell Death Dis 2024; 15:255.</Citation></Reference><Reference><Citation>Singh T, Neal A, Dibernardo G, Raheseparian N, Moatamed NA, Memarzadeh S. Efficacy of birinapant in combination with carboplatin in targeting platinum-resistant epithelial ovarian cancers. Int J Oncol 2022; 60:35.</Citation></Reference><Reference><Citation>Fischer K, Tognarelli S, Roesler S, Boedicker C, Schubert R, Steinle A, et al. The Smac mimetic BV6 improves NK cell-mediated killing of rhabdomyosarcoma cells by simultaneously targeting tumor and effector cells. Front Immunol 2017; 8:202.</Citation></Reference><Reference><Citation>Lindemann C, Marschall V, Weigert A, Klingebiel T, Fulda S. Smac mimetic-induced upregulation of CCL2/MCP-1 triggers migration and invasion of glioblastoma cells and influences the tumor microenvironment in a paracrine manner. Neoplasia 2015; 17:481&#x2013;489.</Citation></Reference><Reference><Citation>Cerna D, Lim B, Adelabu Y, Yoo S, Carter D, Fahim A, et al. SMAC mimetic/IAP inhibitor birinapant enhances radiosensitivity of glioblastoma multiforme. Radiat Res 2021; 195:549&#x2013;560.</Citation></Reference><Reference><Citation>Noonan AM, Cousins A, Anderson D, Zeligs KP, Bunch K, Hernandez L, et al. Matrix drug screen identifies synergistic drug combinations to augment SMAC mimetic activity in ovarian cancer. Cancers (Basel) 2020; 12:3784.</Citation></Reference><Reference><Citation>Petrucci E, Pasquini L, Bernabei M, Saulle E, Biffoni M, Accarpio F, et al. A small molecule SMAC mimic LBW242 potentiates TRAIL- and anticancer drug-mediated cell death of ovarian cancer cells. PLoS One 2012; 7:e35073.</Citation></Reference><Reference><Citation>Mao HL, Pang Y, Zhang X, Yang F, Zheng J, Wang Y, Liu P. Smac peptide potentiates TRAIL- or paclitaxel-mediated ovarian cancer cell death in vitro and in vivo. Oncol Rep 2013; 29:515&#x2013;522.</Citation></Reference><Reference><Citation>Davoodi-Moghaddam Z, Jafari-Raddani F, Delshad M, Pourbagheri-Sigaroodi A, Bashash D. Inhibitors of the PI3K/AKT/mTOR pathway in human malignancies; trend of current clinical trials. J Cancer Res Clin Oncol 2023; 149:15293&#x2013;15310.</Citation></Reference><Reference><Citation>Song M, Bode AM, Dong Z, Lee MH. AKT as a therapeutic target for cancer. Cancer Res 2019; 79:1019&#x2013;1031.</Citation></Reference><Reference><Citation>Duan J, Zhang Z, Du J, Zhang J, Li M, Li C. Esomeprazole alleviates cisplatin resistance by inhibiting the AKT/mTOR pathway in ovarian cancer cells. Onco Targets Ther 2023; 16:425&#x2013;440.</Citation></Reference><Reference><Citation>Liu H, Zhu Y, Niu H, Jie J, Hua S, Bai X, et al. Activation of PI3K/Akt pathway by G protein-coupled receptor 37 promotes resistance to cisplatin-induced apoptosis in non-small cell lung cancer. Cancer Med. 2023; 12:19777&#x2013;19793.</Citation></Reference><Reference><Citation>Zhang M, Wang J, Guo Y, Yue H, Zhang L. Activation of PI3K/AKT/mTOR signaling axis by UBE2S inhibits autophagy leading to cisplatin resistance in ovarian cancer. J Ovarian Res 2023; 16:240.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39423312</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1473-5741</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>16</Day></PubDate></JournalIssue><Title>Anti-cancer drugs</Title><ISOAbbreviation>Anticancer Drugs</ISOAbbreviation></Journal><ArticleTitle>Prophylactic role of pentoxifylline against paclitaxel-induced neuropathy among patients with breast cancer: a randomized-controlled trial.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1097/CAD.0000000000001666</ELocationID><Abstract><AbstractText>Paclitaxel-induced peripheral neuropathy (PN) is a significant clinical concern for which no approved treatment is currently available. The purpose of this trial was to investigate the neuro-prophylactic impact of pentoxifylline against paclitaxel-induced PN in patients diagnosed with breast cancer (BC). BC patients who were assigned to paclitaxel chemotherapy were randomly allocated to pentoxifylline or a control group for 12 weeks. The main outcomes included the assessment of PN incidence according to the defined Common Terminology Criteria for Adverse Events, quality of life (QoL) using the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-NTx) scale, and neuropathic pain using the scale of self-reported Leeds Assessment for Neuropathic Symptoms and Signs (s-LANSS). The code of the clinical trial registration is NCT06562998. The current study included a total of 72 patients allocated into pentoxifylline arm (n = 35) and placebo arm (n = 37). By the 12th week, the prevalence of PN (grade 2 or 3) was significantly lower in the pentoxifylline arm 10/35 (28.6%) compared to 24/37 (64.9%) of the controls (P value = 0.016). The total FACT/GOG-NTx score indicated a considerably worse QoL in the control group [98.18 (10.2) vs. 81.43 (14.8) for pentoxifylline and the control group, respectively, P &lt; 0.001] with a mean difference of -16.75 [95% confidence interval (CI): -23.97 to -9.53]. S-LANSS scale showed significantly higher scores after 6 weeks [13.72 (5.86) vs. 17.52 (3.16), P = 0.002] and 12 weeks [17.84 (4.25) vs. 23.80 (1.00), P &lt; 0.001] for pentoxifylline and control group, respectively. In conclusion, the use of pentoxifylline showed a significant reduction in paclitaxel-induced PN, which improved their QoL.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 Wolters Kluwer Health, Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kidwani</LastName><ForeName>Mariam A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Clinical Oncology Department, Beni-Suef University Hospital.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Osama</LastName><ForeName>Hasnaa</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Clinical Pharmacy Department, Faculty of Pharmacy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hassan</LastName><ForeName>Ahmed</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Clinical Oncology Department, Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abdelrahim</LastName><ForeName>Mohamed E A</ForeName><Initials>MEA</Initials><AffiliationInfo><Affiliation>Clinical Pharmacy Department, Faculty of Pharmacy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Anticancer Drugs</MedlineTA><NlmUniqueID>9100823</NlmUniqueID><ISSNLinking>0959-4973</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>18</Day><Hour>18</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>18</Day><Hour>18</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>18</Day><Hour>14</Hour><Minute>32</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39423312</ArticleId><ArticleId IdType="doi">10.1097/CAD.0000000000001666</ArticleId><ArticleId IdType="pii">00001813-990000000-00328</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M, et al. Current and future burden of breast cancer: global statistics for 2020 and 2040. Breast 2022; 66:15&#x2013;23.</Citation></Reference><Reference><Citation>Ibrahim AS, Khaled HM, Mikhail NN, Baraka H, Kamel H. Cancer incidence in Egypt: results of the national population-based cancer registry program. J Cancer Epidemiol 2014; 2014:437971.</Citation></Reference><Reference><Citation>Yuan P, Ma N, Xu B. Poly (adenosine diphosphate&#x2010;ribose) polymerase inhibitors in the treatment of triple&#x2010;negative breast cancer with homologous repair deficiency. Med Res Rev 2024; 44:2774&#x2013;2792.</Citation></Reference><Reference><Citation>Hurvitz SA, McAndrew NP, Bardia A, Press MF, Pegram M, Crown JP, et al. A careful reassessment of anthracycline use in curable breast cancer. NPJ Breast Cancer 2021; 7:134.</Citation></Reference><Reference><Citation>Mosca L, Ilari A, Fazi F, Assaraf YG, Colotti G. Taxanes in cancer treatment: activity, chemoresistance and its overcoming. Drug Resist Updat 2021; 54:100742.</Citation></Reference><Reference><Citation>Gallego-Jara J, Lozano-Terol G, Sola-Mart&#xed;nez RA, C&#xe1;novas-D&#xed;az M, de Diego Puente T. A compressive review about Taxol&#xae;: history and future challenges. Molecules 2020; 25:5986.</Citation></Reference><Reference><Citation>Tian H, Ma D, Tan X, Yan W, Wu X, He C, et al. Platinum and taxane based adjuvant and neoadjuvant chemotherapy in early triple-negative breast cancer: a narrative review. Front Pharmacol 2021; 12:770663.</Citation></Reference><Reference><Citation>Timmins HC, Li T, Kiernan MC, Baron-Hay S, Marx G, Boyle F, et al. Taxane-induced peripheral neuropathy: differences in patient report and objective assessment. Support Care Cancer 2020; 28:4459&#x2013;4466.</Citation></Reference><Reference><Citation>Timmins HC, Li T, Trinh T, Kiernan MC, Harrison M, Boyle F, et al. Weekly paclitaxel&#x2010;induced neurotoxicity in breast cancer: outcomes and dose response. Oncologist 2021; 26:366&#x2013;374.</Citation></Reference><Reference><Citation>Rizal R. Efficacy of metformin in the prevention and management of paclitaxel chemotherapy-induced peripheral neuropathy: a systematic literature review. BioSci. Med. J. Biomed. Transl. Res 2024; 8:4363&#x2013;4368.</Citation></Reference><Reference><Citation>Desforges AD, Hebert CM, Spence AL, Reid B, Dhaibar HA, Cruz-Topete D, et al. Treatment and diagnosis of chemotherapy-induced peripheral neuropathy: an update. Biomed Pharmacother 2022; 147:112671.</Citation></Reference><Reference><Citation>Bao T, Basal C, Seluzicki C, Li SQ, Seidman AD, Mao JJ. Long-term chemotherapy-induced peripheral neuropathy among breast cancer survivors: prevalence, risk factors, and fall risk. Breast Cancer Res Treat 2016; 159:327&#x2013;333.</Citation></Reference><Reference><Citation>Mahmoud AMAS, El Said NO, Shash E, Ateyya H. Prevention of paclitaxel-induced peripheral neuropathy: literature review of potential pharmacological interventions. Futur J Pharm Sci 2024; 10:67.</Citation></Reference><Reference><Citation>Avallone A, Bimonte S, Cardone C, Cascella M, Cuomo A. Pathophysiology and therapeutic perspectives for chemotherapy-induced peripheral neuropathy. Anticancer Res 2022; 42:4667&#x2013;4678.</Citation></Reference><Reference><Citation>Davis MP. Novel drug treatments for pain in advanced cancer and serious illness: a focus on neuropathic pain and chemotherapy-induced peripheral neuropathy. Palliat Care Soc Pract 2024; 18:26323524241266604.</Citation></Reference><Reference><Citation>Salama RAM, Raafat FA, Hasanin AH, Hendawy N, Saleh LA, Habib EK, et al. A neuroprotective effect of pentoxifylline in rats with diabetic neuropathy: mitigation of inflammatory and vascular alterations. Int Immunopharmacol 2024; 128:111533.</Citation></Reference><Reference><Citation>Kalli S, Semine A, Cohen S, Naber SP, Makim SS, Bahl M. American Joint Committee on Cancer&#x2019;s Staging System for breast cancer: what the radiologist needs to know. Radiographics 2018; 38:1921&#x2013;1933.</Citation></Reference><Reference><Citation>Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5:649&#x2013;655.</Citation></Reference><Reference><Citation>Shah S. Common terminology criteria for adverse events. Natl Cancer Inst USA 2022; 784:785.</Citation></Reference><Reference><Citation>Bennett MI, Smith BH, Torrance N, Potter J. The S-LANSS score for identifying pain of predominantly neuropathic origin: validation for use in clinical and postal research. J Pain 2005; 6:149&#x2013;158.</Citation></Reference><Reference><Citation>Koc R, Erdemoglu AK. Validity and reliability of the Turkish Self-administered Leeds Assessment of Neuropathic Symptoms and Signs (S-LANSS) questionnaire. Pain Med 2010; 11:1107&#x2013;1114.</Citation></Reference><Reference><Citation>Ea C. Psychometric evaluation of the Functional Assessment Of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy. Int J Gynecol Cancer 2003; 13:741&#x2013;748.</Citation></Reference><Reference><Citation>Cheng HL, Lopez V, Lam SC, Leung AKT, Li YC, Wong KH, et al. Psychometric testing of the Functional Assessment Of Cancer Therapy/Gynecologic Oncology Group&#x2014;Neurotoxicity (FACT/GOG-Ntx) subscale in a longitudinal study of cancer patients treated with chemotherapy. Health Qual Life Outcomes 2020; 18:1&#x2013;9.</Citation></Reference><Reference><Citation>Khalefa HG, Shawki MA, Aboelhassan R, El Wakeel LM. Evaluation of the effect of N-acetylcysteine on the prevention and amelioration of paclitaxel-induced peripheral neuropathy in breast cancer patients: a randomized controlled study. Breast Cancer Res Treat 2020; 183:117&#x2013;125.</Citation></Reference><Reference><Citation>Salehifar E, Janbabaei G, Hendouei N, Alipour A, Tabrizi N, Avan R. Comparison of the efficacy and safety of pregabalin and duloxetine in taxane-induced sensory neuropathy: a randomized controlled trial. Clin Drug Investig 2020; 40:249&#x2013;257.</Citation></Reference><Reference><Citation>Diggle P. Analysis of Longitudinal Data. Oxford University Press; 2002.</Citation></Reference><Reference><Citation>Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457&#x2013;481.</Citation></Reference><Reference><Citation>Zaj&#x105;czkowska R, Kocot-K&#x119;pska M, Leppert W, Wrzosek A, Mika J, Wordliczek J. Mechanisms of chemotherapy-induced peripheral neuropathy. Int J Mol Sci 0129; 20:1451.</Citation></Reference><Reference><Citation>Sa&#x142;at K. Chemotherapy-induced peripheral neuropathy: part 1&#x2014;current state of knowledge and perspectives for pharmacotherapy. Pharmacol Rep 2020; 72:486&#x2013;507.</Citation></Reference><Reference><Citation>Liu J, Feng X, Yu M, Xie W, Zhao X, Li W, et al. Pentoxifylline attenuates the development of hyperalgesia in a rat model of neuropathic pain. Neurosci Lett 2007; 412:268&#x2013;272.</Citation></Reference><Reference><Citation>Vakili A, Shirvanian MJ, Safakhah HA, Rashidy-Pour A. Pentoxifylline decreases allodynia and hyperalgesia in a rat model of neuropathic pain. Daru 2011; 19:306&#x2013;311.</Citation></Reference><Reference><Citation>Kim HK, Hwang SH, Sing-Ong L, Kim SH, Abdi S. Pentoxifylline ameliorates mechanical hyperalgesia in a rat model of chemotherapy-induced neuropathic pain. Pain Physician 2016; 19:E589.</Citation></Reference><Reference><Citation>Fumagalli G, Monza L, Cavaletti G, Rigolio R, Meregalli C. Neuroinflammatory process involved in different preclinical models of chemotherapy-induced peripheral neuropathy. Front Immunol 2021; 11:626687.</Citation></Reference><Reference><Citation>Baykal S, Boz C, &#xc7;akir E, Baytan SH, Karaku&#x15f; M, Kuzeyli K. The effects of pentoxifylline in experimental nerve injury. Turkish J Med Sci 2002; 32:207&#x2013;210.</Citation></Reference><Reference><Citation>Garcia FA de O, Rebou&#xe7;as JF, Balbino TQ, et al. Pentoxifylline reduces the inflammatory process in diabetic rats: relationship with decreases of pro-inflammatory cytokines and inducible nitric oxide synthase. J Inflamm 2015; 12:1&#x2013;10.</Citation></Reference><Reference><Citation>Thomaier L, Jewett P, Brown K, Gotlieb R, Teoh D, Blaes AH, et al. The associations between physical activity, neuropathy symptoms and health-related quality of life among gynecologic cancer survivors. Gynecol Oncol 2020; 158:361&#x2013;365.</Citation></Reference><Reference><Citation>Bakry HM, Mansour NO, ElKhodary TR, Soliman MM. Efficacy of metformin in prevention of paclitaxel-induced peripheral neuropathy in breast cancer patients: a randomized controlled trial. Front Pharmacol 2023; 14:1181312.</Citation></Reference><Reference><Citation>Okuyama H, Nakamura S, Akashi-Tanaka S, Sawada T, Kuwayama T, Handa S, Kato Y. QOL evaluation of nab-paclitaxel and docetaxel for early breast cancer. Eur J Breast Health 2018; 14:194&#x2013;198.</Citation></Reference><Reference><Citation>Hall E, Cameron D, Waters R, Barrett-Lee P, Ellis P, Russell S, et al.; TACT Trial Investigators. Comparison of patient reported quality of life and impact of treatment side effects experienced with a taxane-containing regimen and standard anthracycline based chemotherapy for early breast cancer: 6 year results from the UK TACT trial (CRUK/01/001). Eur J Cancer 2014; 50:2375&#x2013;2389.</Citation></Reference><Reference><Citation>Crevenna R, Ashbury FD. Physical interventions for patients suffering from chemotherapy-induced polyneuropathy. Support Care Cancer 2018; 26:1017&#x2013;1018.</Citation></Reference><Reference><Citation>Hammond EA, Pitz M, Lambert P, Shay B. Quantitative sensory profiles of upper extremity chemotherapy induced peripheral neuropathy: are there differences in sensory profiles for neuropathic versus nociceptive pain? Can J Pain 2019; 3:169&#x2013;177.</Citation></Reference><Reference><Citation>Polomano RC, Farrar JT. Pain and neuropathy in cancer survivors: surgery, radiation, and chemotherapy can cause pain; research could improve its detection and treatment. Cancer Nurs 2006; 29:39&#x2013;47.</Citation></Reference><Reference><Citation>Zocca J, Valimahomed A, Yu J, Gulati A. A review of Recent Advances in the Management of Breast Cancer Related Pain. Breast Cancer Management 2018; 7:BMT08&#x2013;83. https://doi.org/10.2217/bmt-2018-0003.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/bmt-2018-0003</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizrahi D, Park SB, Li T, Timmins HC, Trinh T, Au K, et al. Hemoglobin, body mass index, and age as risk factors for paclitaxel-and oxaliplatin-induced peripheral neuropathy. JAMA Netw open 2021; 4:e2036695&#x2013;e2036695.</Citation></Reference><Reference><Citation>Saito T, Okamura A, Inoue J, Makiura D, Doi H, Yakushijin K, et al. Anemia is a novel predictive factor for the onset of severe chemotherapy-induced peripheral neuropathy in lymphoma patients receiving rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy. Oncol Res 2019; 27:469&#x2013;474.</Citation></Reference><Reference><Citation>Zhu W, Xu B. Association of pretreatment anemia with pathological response and survival of breast cancer patients treated with neoadjuvant chemotherapy: a population-based study. PLoS One 2015; 10:e0136268.</Citation></Reference><Reference><Citation>Ozturk B, Egehan I, Atavci S, Kitapci M. Pentoxifylline in the prevention of radiation-induced lung toxicity in patients with breast and lung cancer: a double-blind randomized trial. Int J Radiat Oncol Biol Phys 2004; 58:213&#x2013;219.</Citation></Reference><Reference><Citation>Aygenc E, Celikkanat S, Kaymakci M, Aksaray F, Ozdem C. Prophylactic effect of pentoxifylline on radiotherapy complications: a clinical study. Otolaryngol Head Neck Surg 2004; 130:351&#x2013;356.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39423293</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>18</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>18</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2160-3251</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>4</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>01</Day></PubDate></JournalIssue><Title>JBJS case connector</Title><ISOAbbreviation>JBJS Case Connect</ISOAbbreviation></Journal><ArticleTitle>Arthroscopic Resection of Acromioclavicular Joint Cysts and Distal Clavicle: A Report of 3 Cases.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">e24.00297</ELocationID><Abstract><AbstractText Label="CASE" NlmCategory="METHODS">This case report describes 3 patients who developed acromioclavicular joint cysts secondary to rotator cuff arthropathy. The patients underwent arthroscopic cyst decompression and distal clavicle resection, resulting in successful excision of the cyst and minimal cyst recurrence.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Based on these cases, arthroscopic cyst decompression with concomitant distal clavicle resection should be considered as an effective alternative to serial aspirations or open cyst excision and distal clavicle resection.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 by The Journal of Bone and Joint Surgery, Incorporated.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Anna B</ForeName><Initials>AB</Initials><Identifier Source="ORCID">0000-0001-5385-1456</Identifier><AffiliationInfo><Affiliation>Sports Medicine Institute, Hospital for Special Surgery, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Inclan</LastName><ForeName>Paul M</ForeName><Initials>PM</Initials><Identifier Source="ORCID">0000-0003-0819-0446</Identifier></Author><Author ValidYN="Y"><LastName>Thacher</LastName><ForeName>Ryan R</ForeName><Initials>RR</Initials></Author><Author ValidYN="Y"><LastName>Gulotta</LastName><ForeName>Lawrence V</ForeName><Initials>LV</Initials><Identifier Source="ORCID">0000-0002-4094-4781</Identifier></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D002363">Case Reports</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JBJS Case Connect</MedlineTA><NlmUniqueID>101596828</NlmUniqueID><ISSNLinking>2160-3251</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000173" MajorTopicYN="Y">Acromioclavicular Joint</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001182" MajorTopicYN="Y">Arthroscopy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002968" MajorTopicYN="Y">Clavicle</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003560" MajorTopicYN="N">Cysts</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000070656" MajorTopicYN="N">Rotator Cuff Tear Arthropathy</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Disclosure: The Disclosure of Potential Conflicts of Interest forms are provided with the online version of the article (http://links.lww.com/JBJSCC/C457).</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>18</Day><Hour>18</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>18</Day><Hour>18</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>18</Day><Hour>14</Hour><Minute>12</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39423293</ArticleId><ArticleId IdType="doi">10.2106/JBJS.CC.24.00297</ArticleId><ArticleId IdType="pii">01709767-202412000-00012</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hiller AD, Miller JD, Zeller JL. Acromioclavicular joint cyst formation. Clin Anat. 2010;23(2):145-52.</Citation></Reference><Reference><Citation>Murena L, D&#x2019;angelo F, Falvo DA, Vulcano E. Surgical treatment of an aseptic fistulized acromioclavicular joint cyst: a case report and review of the literature. Cases J. 2009;2:8388.</Citation></Reference><Reference><Citation>Tham SYY, Ng PHJ, Phua SKA, Ho SWL. Aspiration of a large acromioclavicular joint cyst complicated by recurrence and enlargement: a case report. Cureus. 2023;15(2):e34754.</Citation></Reference><Reference><Citation>Christodoulou KC, Kakagia DD, Galanis VG, Tsoucalas GI, Fiska AT. Gigantic acromioclavicular joint cyst: presentation and mini review. J Shoulder Elbow Surg. 2021;30(1):e18-24.</Citation></Reference><Reference><Citation>Groh GI, Badwey TM, Rockwood CAJ. Treatment of cysts of the acromioclavicular joint with shoulder hemiarthroplasty. J Bone Joint Surg Am. 1993;75(12):1790-4.</Citation></Reference><Reference><Citation>Mullett H, Benson R, Levy O. Arthroscopic treatment of a massive acromioclavicular joint cyst. Arthroscopy. 2007;23(4):446.e1-446.e4464.</Citation></Reference><Reference><Citation>Craig EV. The geyser sign and torn rotator cuff: clinical significance and pathomechanics. Clin Orthop Relat Res. 1984;191:213-5.</Citation></Reference><Reference><Citation>Cooper HJ, Milillo R, Klein DA, DiFelice GS. The MRI geyser sign: acromioclavicular joint cysts in the setting of a chronic rotator cuff tear. Am J Orthop (Belle Mead NJ). 2011;40(6):E118-121.</Citation></Reference><Reference><Citation>Hattori Y, Imai S, Nakamura Hara R, Niu A. Acromioclavicular joint cyst treated with excision and anterolateral thigh flap reconstruction. Plast Reconstr Surg Glob Open. 2021;9(2):e3412.</Citation></Reference><Reference><Citation>Postacchini F, Perugia D, Gumina S. Acromioclavicular joint cyst associated with rotator cuff tear. A report of three cases. Clin Orthop Relat Res. 1993;294:111-3.</Citation></Reference><Reference><Citation>Cho CH. Complicated acromioclavicular joint cyst with massive rotator cuff tear. Am J Orthop (Belle Mead NJ). 2014;43(2):70-3.</Citation></Reference><Reference><Citation>Zhang Y, Old J. Massive acromioclavicular joint cyst with intramuscular extension: case report and review. Case Rep Orthop. 2018;2018:7602549.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39423284</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>18</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2470-9468</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>100</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>18</Day></PubDate></JournalIssue><Title>Science immunology</Title><ISOAbbreviation>Sci Immunol</ISOAbbreviation></Journal><ArticleTitle>Programmable bacteria synergize with PD-1 blockade to overcome cancer cell-intrinsic immune resistance mechanisms.</ArticleTitle><Pagination><StartPage>eadn9879</StartPage><MedlinePgn>eadn9879</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/sciimmunol.adn9879</ELocationID><Abstract><AbstractText>Interferon-&#x3b3; (IFN-&#x3b3;) is a potent cytokine critical for response to immunotherapy, yet conventional methods to systemically deliver this cytokine have been hindered by severe dose-limiting toxicities. Here, we engineered a strain of probiotic bacteria that home to tumors and locally release IFN-&#x3b3;. A single intratumoral injection of these IFN-&#x3b3;-producing bacteria was sufficient to drive systemic tumor antigen-specific antitumor immunity, without observable toxicity. Although cancer cells use various resistance mechanisms to evade immune responses, bacteria-derived IFN-&#x3b3; overcame primary resistance to programmed cell death 1 (PD-1) blockade via activation of cytotoxic Foxp3<sup>-</sup>CD4<sup>+</sup> and CD8<sup>+</sup> T cells. Moreover, by activating natural killer (NK) cells, bacteria-derived IFN-&#x3b3; also overcame acquired resistance mechanisms to PD-1 blockade, specifically loss-of-function mutations in IFN-&#x3b3; signaling and antigen presentation pathways. Collectively, these results demonstrate the promise of combining IFN-&#x3b3;-producing bacteria with PD-1 blockade as a therapeutic strategy for overcoming immunotherapy-resistant, locally advanced, and metastatic disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Fangda</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-4697-3989</Identifier><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Zaofeng</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0000-0003-4861-9729</Identifier><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Savage</LastName><ForeName>Thomas M</ForeName><Initials>TM</Initials><Identifier Source="ORCID">0000-0002-6618-2973</Identifier><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vincent</LastName><ForeName>Rosa L</ForeName><Initials>RL</Initials><Identifier Source="ORCID">0000-0003-0742-8977</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Engineering, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Los Santos-Alexis</LastName><ForeName>Kenia</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-3628-9796</Identifier><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahn</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-4868-3149</Identifier><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rouanne</LastName><ForeName>Mathieu</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-2970-4821</Identifier><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mariuzza</LastName><ForeName>Dylan L</ForeName><Initials>DL</Initials><Identifier Source="ORCID">0000-0002-9369-2514</Identifier><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Danino</LastName><ForeName>Tal</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0003-2713-7659</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Engineering, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Data Science Institute, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arpaia</LastName><ForeName>Nicholas</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-0657-0528</Identifier><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Immunol</MedlineTA><NlmUniqueID>101688624</NlmUniqueID><ISSNLinking>2470-9468</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061026">Programmed Cell Death 1 Receptor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>82115-62-6</RegistryNumber><NameOfSubstance UI="D007371">Interferon-gamma</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061026" MajorTopicYN="Y">Programmed Cell Death 1 Receptor</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="Y">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000082082" MajorTopicYN="Y">Immune Checkpoint Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007371" MajorTopicYN="N">Interferon-gamma</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>18</Day><Hour>18</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>18</Day><Hour>18</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>18</Day><Hour>14</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39423284</ArticleId><ArticleId IdType="doi">10.1126/sciimmunol.adn9879</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39423274</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>18</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2375-2548</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>42</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>18</Day></PubDate></JournalIssue><Title>Science advances</Title><ISOAbbreviation>Sci Adv</ISOAbbreviation></Journal><ArticleTitle>Multivalent supramolecular fluorescent probes for accurate disease imaging.</ArticleTitle><Pagination><StartPage>eadp8719</StartPage><MedlinePgn>eadp8719</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/sciadv.adp8719</ELocationID><Abstract><AbstractText>Optical imaging is a powerful tool for early disease detection and effective treatment planning, but its accuracy is often compromised by the uptake of imaging materials by the mononuclear phagocyte system (MPS). Herein, we leverage multivalent host-guest interactions between cyanine dyes and &#x3b2;-cyclodextrin polymers to develop supramolecular probes with enhanced stability, optical, and transport profiles for accurate in vivo imaging. These multivalent interactions not only ensure the stability of the probes but also enhance fluorescence efficiency by minimizing nonradiative decay. Our self-assembly approach effectively modulates probe size and surface properties, enabling evasion of MPS clearance and promoting prolonged bloodstream circulation, thereby improving the signal-to-background ratio for imaging. The effectiveness of our design is demonstrated by substantial advancements in the early diagnosis of acute kidney injury and by providing high-contrast imaging and precise surgical navigation across various tumor models. Our strategy not only advances optical imaging materials toward clinical translation but also establishes a versatile platform applicable to multiple imaging modalities.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Qian</ForeName><Initials>Q</Initials><Identifier Source="ORCID">0009-0006-3895-7766</Identifier><AffiliationInfo><Affiliation>State Key Laboratory for Chemo/Bio-Sensing and Chemometrics, College of Chemistry and Chemical Engineering, Hunan University, Changsha 410082, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Zhixuan</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0000-0001-8295-5860</Identifier><AffiliationInfo><Affiliation>State Key Laboratory for Chemo/Bio-Sensing and Chemometrics, College of Chemistry and Chemical Engineering, Hunan University, Changsha 410082, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Li</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>State Key Laboratory for Chemo/Bio-Sensing and Chemometrics, College of Chemistry and Chemical Engineering, Hunan University, Changsha 410082, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhong</LastName><ForeName>Haichen</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>State Key Laboratory for Chemo/Bio-Sensing and Chemometrics, College of Chemistry and Chemical Engineering, Hunan University, Changsha 410082, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiong</LastName><ForeName>Bin</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-1575-5954</Identifier><AffiliationInfo><Affiliation>State Key Laboratory for Chemo/Bio-Sensing and Chemometrics, College of Chemistry and Chemical Engineering, Hunan University, Changsha 410082, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ren</LastName><ForeName>Tianbing</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-5774-8306</Identifier><AffiliationInfo><Affiliation>State Key Laboratory for Chemo/Bio-Sensing and Chemometrics, College of Chemistry and Chemical Engineering, Hunan University, Changsha 410082, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Zhe</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0009-0001-2553-9438</Identifier><AffiliationInfo><Affiliation>State Key Laboratory for Chemo/Bio-Sensing and Chemometrics, College of Chemistry and Chemical Engineering, Hunan University, Changsha 410082, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yuan</LastName><ForeName>Lin</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-1015-5319</Identifier><AffiliationInfo><Affiliation>State Key Laboratory for Chemo/Bio-Sensing and Chemometrics, College of Chemistry and Chemical Engineering, Hunan University, Changsha 410082, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xiao-Bing</ForeName><Initials>XB</Initials><Identifier Source="ORCID">0000-0002-4010-0028</Identifier><AffiliationInfo><Affiliation>State Key Laboratory for Chemo/Bio-Sensing and Chemometrics, College of Chemistry and Chemical Engineering, Hunan University, Changsha 410082, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Adv</MedlineTA><NlmUniqueID>101653440</NlmUniqueID><ISSNLinking>2375-2548</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005456">Fluorescent Dyes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047392">beta-Cyclodextrins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002232">Carbocyanines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005456" MajorTopicYN="Y">Fluorescent Dyes</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061848" MajorTopicYN="Y">Optical Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D047392" MajorTopicYN="N">beta-Cyclodextrins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058186" MajorTopicYN="N">Acute Kidney Injury</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002232" MajorTopicYN="N">Carbocyanines</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>18</Day><Hour>18</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>18</Day><Hour>18</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>18</Day><Hour>14</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39423274</ArticleId><ArticleId IdType="doi">10.1126/sciadv.adp8719</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>